Ari Maizel, Chief Commercial Officer at Axsome Therapeutics ($AXSM), made one open market sale of company shares in the last year, totaling $1.38 million. His most recent sale occurred on January 21, 2026. These transactions rank 4,210th among 11,678 individual insiders in our database, where the average sale amount is $8.6 million across about 6.4 transactions. Ari Maizel reported no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 26, 2026 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | A | Restricted Stock Units | 16385 | $0.00 | 16,385.0000 | 50,412,640 | 9999.99% | 0.03% |
| Jan. 21, 2026 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | M | Common Stock | 7500 | $70.73 | 7,500.0000 | 50,412,640 | 9999.99% | 0.01% |
| Jan. 21, 2026 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | S | Common Stock | 7500 | $184.44 | 0.0000 | 50,412,640 | 100.00% | 0.01% |
| Jan. 21, 2026 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | M | Stock Option (Right to Buy) | 7500 | $0.00 | 31,210.0000 | 50,412,640 | 19.37% | 0.01% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | A | Restricted Stock Units | 7740 | $0.00 | 7,740.0000 | 48,765,403 | 9999.99% | 0.02% |
| Feb. 24, 2025 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | A | Performance Stock Units | 7740 | $0.00 | 7,740.0000 | 48,765,403 | 9999.99% | 0.02% |
| Feb. 21, 2025 | Axsome Therapeutics, Inc. | $AXSM | Maizel Ari | Chief Commercial Officer | A | Employee Stock Option (Right to Buy) | 7816 | $0.00 | 7,816.0000 | 48,765,403 | 9999.99% | 0.02% |